Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Friesen, InnaSaluzzo, Francesca
Groenheit, Ramona
Aubry, Alexandra
Anthony, Richard
Niemann, Stefan
Mathys, Vanessa
Cirillo, Daniela Maria
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al.Published in
Clin Microbiol Infect 2024; 30(9):1204-1206PMID
38851424ae974a485f413a2113503eed53cd6c53
10.1016/j.cmi.2024.06.001
Scopus Count
Collections
Related articles
- Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
- Authors: Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C, Tuberculosis Network European Trials group
- Issue date: 2024 Sep
- Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response.
- Authors: Lange C, Kherabi Y, Guglielmetti L, Duarte R, Günther G, Tuberculosis Network European Trials group
- Issue date: 2024 Sep
- Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.
- Authors: Otto-Knapp R, Edwards S, Kuchukhidze G, Kröger S, Häcker B, Bivol S, Yedilbayev A
- Issue date: 2024 Apr
- [Advances in chemotherapy of multidrug-resistant and rifampicin-resistant tuberculosis].
- Authors: Liu SS, Wang LZ, Tang SJ
- Issue date: 2020 Apr 12
- Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
- Authors: James LP, Klaassen F, Sweeney S, Furin J, Franke MF, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies NA
- Issue date: 2024 May